JournalArta
Monday, November 23, 2026 · JakartaS&P 6,910.39 ▼3.70%USD/IDR 18,158 ▼0.42%
JournalArta
Global Edition
beyond headlines
Advertisement

Eli Lilly’s Next Weight-Loss Drug Shows 54.1-Pound Loss

Eli Lilly’s experimental EloraTZP produced average weight loss of up to 54.1 pounds in an early-stage trial of people with obesity and Type 2 diabetes. The results arrive as the company raises its revenue outlook and faces a new classwide warning for its existing weight-loss drugs.

By Elena Vance
WIB2 min read
Eli Lilly’s Next Weight-Loss Drug Shows 54.1-Pound Loss
Eli Lilly’s Next Weight-Loss Drug Shows 54.1-Pound Loss)

Eli Lilly’s next weight-loss drug produced average weight loss of up to 54.1 pounds at 48 weeks in an early-stage trial, the company reported at ObesityWeek on November 14 and 15. The treatment, EloraTZP, was tested in people with obesity and Type 2 diabetes.

EloraTZP is not yet approved. The drug combines tirzepatide, the active ingredient in Lilly’s Zepbound and Mounjaro, with an experimental drug called eloralintide.

Up to 77% of trial participants reached normal blood sugar levels. The study was a Phase 2 trial, an early stage of drug testing.

Lilly shares gained 25% this year, compared with a 19% rise for the Health Care Select Sector SPDR Fund over the same period. The stock also rose 9% in the preceding month and sat 8.6% below its record high of $1,475.25.

Advertisement

Retatrutide trials target other conditions

Lilly’s experimental retatrutide reduced sleep-related breathing disruptions by up to 60.6% at 80 weeks in a Phase 3 trial. In another late-stage trial, the drug reduced knee arthritis pain by up to 75.8% at 68 weeks.

Those studies tested the drug against health problems often linked to obesity. Phase 3 trials are a later stage of drug testing than the EloraTZP study.

Lilly held about 61% of the US market in the second quarter. It also accounted for about seven in 10 new Medicare patients starting weight-loss drugs.

FDA warning covers drug class

On November 9, the Food and Drug Administration required a new warning for all GLP-1 drugs, including Lilly’s Mounjaro and Zepbound. The warning concerns a rare eye condition that can cause sudden vision loss.

Advertisement

The regulator reviewed 126 clinical trials. It found about six cases a year for every 100,000 patients taking GLP-1 drugs, compared with about four among patients not taking them.

The FDA has not established that the drugs caused the condition. Lilly shares nevertheless stayed near their record highs after the warning.

Lilly raises revenue outlook

Lilly reported third-quarter 2026 revenue of $24.4 billion on October 29, an increase of 39% from a year earlier. Revenue exceeded analyst estimates by roughly $2 billion.

Adjusted earnings per share rose 7% to $7.48, beating the $6.26 consensus estimate. Mounjaro sales grew 65%, while Zepbound sales rose 49%.

The company raised its full-year revenue forecast to $91 billion to $92 billion from $85 billion to $87 billion. It trimmed its earnings-per-share outlook to $35 to $36 because of one-time charges tied to recent acquisitions.

Eli Lilly
Advertisement
What Kind of Holiday Spender Are You? Take the Black Friday QuizTake the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1GTA 6 Draws Review Bombing on MetacriticGTA 6 Draws Review Bombing on Metacritic
  2. 2Dow Jones Futures Await Reopening After Tech Stocks SlideDow Jones Futures Await Reopening After Tech Stocks Slide
  3. 3Jensen Huang Denies Abuse Claims After Nvidia ExitJensen Huang Denies Abuse Claims After Nvidia Exit
  4. 4Micron Says Memory Has Changed as Shares Fall 13.89%Micron Says Memory Has Changed as Shares Fall 13.89%
  5. 5Brielle Biermann Marries Billy Seidl in Naples, FloridaBrielle Biermann Marries Billy Seidl in Naples, Florida
Advertisement
Don't Miss

Latest News

All stories →
  1. US Army Plans Iowa Blast Despite Court-Ordered PauseWorld · United StatesUS Army Plans Iowa Blast Despite Court-Ordered PauseNov 23
  2. Australia’s power prices would be up to 50% higher, economist saysBusiness · EnergyAustralia’s power prices would be up to 50% higher, economist saysNov 23
  3. Japan Defeats USA 7-5 to Win Softball All-Star SeriesSport · More SportsJapan Defeats USA 7-5 to Win Softball All-Star SeriesNov 23
  4. Liverpool Spoil Mauricio Pochettino’s Debut With 4-0 WinSport · FootballLiverpool Spoil Mauricio Pochettino’s Debut With 4-0 WinNov 23
  5. Advertisement
  6. Wests Tigers Allow Fainu Loan as Fogarty Talks ContinueSport · More SportsWests Tigers Allow Fainu Loan as Fogarty Talks ContinueNov 23
  7. Endometriosis Study Identifies 27 New Genetic CluesLifestyle · Food & HealthEndometriosis Study Identifies 27 New Genetic CluesNov 23
  8. Labor Risks Losing Heartland Seats in Victoria, Poll FindsWorld · AustraliaLabor Risks Losing Heartland Seats in Victoria, Poll FindsNov 23
  9. Stuffy Nose Remedies Fail When Patients Rely on AntibioticsLifestyleStuffy Nose Remedies Fail When Patients Rely on AntibioticsNov 23